White Matter Hyperintensities as Early and Independent Predictors of Alzheimer's Disease Risk

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S393-S400

  Mortamais, Marion ^a,b   Artero, Sylvaine ^a,b   Ritchie, Karen ^a,b,c  

^a Montpellier 1 University   (France)

^b UNIV MONTPELLIER   (France)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; biomarker; cerebrovascular disease; magnetic resonance imaging; white matter hyperintensities

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HEALTH HAZARD; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPATHOLOGY; PREDICTIVE VALUE; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; WHITE MATTER; WHITE MATTER HYPERINTENSITY; COGNITIVE DEFECT; DISEASE COURSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RISK FACTOR;

ALZHEIMER DISEASE; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; RISK FACTORS; WHITE MATTER;

EID: 84908216330     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141473     Document Type: Review

References (88)

1. Hulette CM,Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM (1998) Neuropathological and neuropsychological changes in "normal" aging: Evidence fo r preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57, 1168-1174.
2. Morris JC, Price JL (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 17, 101-118.
3. Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS (2011) Meta-Analysis of plasma amyloid-beta levels in Alzheimer's disease. J Alzheimers Dis 26, 365-375.
4. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE,Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519.
5. Selkoe DJ (2005) Defining molecular targets to prevent Alzheimer disease. Arch Neurol 62, 192-195.
6. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospi nal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
7. Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P,Wiste HJ,Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 , 207-216.
8. de laTorre JC (2002) Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 33, 1152-1162.
9. Erten-Lyons D, Woltjer R, Kayex J, Mattek N, Dodge HH, Green S, Tran H, Howieson DB, Wild K, Silbert LC (2013) Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 81, 977-983.
10. Honig L S, Kukull W, Mayeux R (2005) Atherosclerosis and AD: Analysis of data from theUSNational Alzheimer's Coordinating Center. Neurology 64, 494-500.
11. Polvikoski TM, van Straaten EC, Barkhof F , Sulkava R, Aronen HJ, Niinisto L, Oinas M, Scheltens P, Erkinjuntti T, Kalaria RN (2010) Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 75, 2071-207 8.
12. Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, Van Deerlin V, Lee VM, Trojanowski JQ, Arnold SE (2012) Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 135, 3749-3756.
13. Tolppanen AM, Solomon A, Soininen H, KivipeltoM(2012) Midlife vascular risk factors and Alzheimer's disease: Evidence from epidemiological studies. J Alzheimers Dis 32, 531-540.
14. Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W(2014) Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol 71, 195-200.
15. Reed BR, Marchant NL, Jagust WJ, DeCarli CC, Mack W, Chui HC (2012) Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging 33, 1979-1987.
16. Hachinski V, Munoz DG (1997) Cerebrovascular pathology in Alzheimer's disease: Cause, effect or epiphenomenon? Ann N Y Acad Sci 826, 1-6.
17. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ (2008) Cerebrovascular dysfunction in amyloid precursor protein tr ansgenic mice: Contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci 28, 13542-13550.
18. Dhikav V, Anand KS (2012) Are vascular factors linked to the development of hippocampal atrophy in Alzheimer's disease? J Alzheimers Dis 32, 711-718.
19. Esiri MM, Nagy Z, Smith MZ, Barnetson L, SmithAD(1999) Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 354, 919-920.
20. van der Flier WM,Middelkoop HA,Weverling-Rijnsburger AW,Admiraal-Behloul F,Spilt A,Bollen EL,Westendorp RG,van Buchem MA 2004 Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD Neurology 62, 1862-1864.
21. Tosto G, Zimmerman ME, Carmichael OT, Brickman AM (2014) Predicting aggressive decline in mild cognitive impairment: The importance of white matter hyperintensities. JAMA Neurol 71, 872-877.
22. Valenzuela M, Esler M, Ritchie K, Brodaty H (2012) Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention. Transl Psychiatry 2, e107.
23. Pantoni L, Garcia JH (1997) Pathogenesis of leukoaraiosis: A review. Stroke 28, 652-659.
24. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC (2002) Subcortical ischaemic vascular dementia. Lancet Neurol 1, 426-436.
25. de Leeuw FE, De Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, BretelerMM(2000) Aortic atherosclerosis at middle age predicts cerebral white matter lesions in the elderly. Stroke 31, 425-429.
26. Greenwald BS, Kramer-Ginsberg E, Krishnan KR, Hu J, Ashtari M, Wu H, Aupperle P, Patel M, Pollack S (2001) A controlled study of MRI signal hyperintensities in olde r depressed patients with and without hypertension. J Am Geriatr Soc 49, 1218-1225.
27. Ylikoski A, Erkinjuntti T, Raininko R, Sarna S, Sulkava R, Tilvis R (1995) White matter hyperinten sities on MRI in the neurologically nondiseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke 26, 1171-1177.
28. Fazekas F, Kleinert R, Offenbacher H, Sc hmidt R, Kleinert G, Payer F, Radner H, Lechner H (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43, 1683-1689.
29. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJ (2011) Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 82, 126-135.
30. Smith EE, Salat DH, Jeng J, McCreary CR, Fischl B, Schmahmann JD, Dickerson BC, Viswanathan A, Albert MS, Blacker D, Greenberg SM (2011) Correlations between MRI white matter lesion l ocation and executive function and episodic memory. Neurology 76, 1492-1499.
31. Mortamais M, Artero S, RitchieK(2013) Cerebral white matter hyperintensities in the prediction of cognitive decline and incident dementia. Int Rev Psychiatry 25, 686-698.
32. Debette S, Markus HS (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-Analysis. BMJ 341, c3666.
33. Brickman AM, Provenzano FA,Muraskin. J, Manly JJ, Blum S, Apa Z, Stern Y, Brown TR, Luchsinger JA, Mayeux R (2012). Re gional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol 69, 1621-1627.
34. Debette S, Beiser A, DeCarli C, Au R, Himali JJ,Kel ly-Hayes M, Romero JR, Kase CS, Wolf PA, Seshadri S (2010) Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: The Framingham Offspring Study. Stroke 41, 600-606.
35. Kuller LH, Lopez OL, Newman A, Beauchamp NJ, Burke G, Dulberg C, Fitzpatrick A, Fried L, Haan MN (2003) Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology 22, 13-22.
36. Meguro K, Ishii H, Kasuya M, AkanumaK,Meguro M, Kasai M, Lee E, Hashimoto R, Yamaguchi S, Asada T (2007) Incidence of dementia and as sociated risk factors in Japan: The Osaki-Tajiri Project. J Neurol Sci 260, 175-182.
37. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2004) Cerebral white matter lesions and the risk of dementia. Arch Neurol 61, 1531-1534.
38. Godin O, Tzourio C, Rouaud O, Zhu Y, Maillard P, Pasquier F, Crivello F, Alperovitch A , Mazoyer B, Dufouil C (2010) Joint effect of white matter lesions and hippocampal volumes on severity of cognitive decline: The 3C-Dijon MRI study. J Alzheimers Dis 20, 453-463.
39. Inaba M, White L, Bell C, Chen R, Petrovitch H, Launer L, Abbott RD, Ross GW,Masaki K (2011) White matter lesions on brain magnetic resonance imaging scan and 5-year cognitive decline: The Honolulu-Asia aging study. J Am Geriatr Soc 59, 1484-1489.
40. Mortamais M, Portet F, Brickman AM, Provenzano FA, Muraskin J, Akbaraly TN, Berr C, Touchon J, Bonafe A, le Bars E, Menjot de Champfleur N, Maller JJ, Meslin C, Sabatier R, Ritchie K, Artero S (2013) Education modulates the impact of white matter lesions on the risk of mild cognitive impairment and dementia. Am J Geriatr Psychiatry. doi: 10.1016/j.jagp.2013.06.002.
41. Prins ND,van Dijk EJ,den Heijer T,Vermeer SE,Jolles J,Koudstaal PJ,Hofman A BretelerMM( 2005 Cerebral smallvessel disease and decline in information processing speed, executive function and memory Brain, 128, 2034-2041.
42. Silbert LC, Howieson DB, Dodge H, Kaye JA (2009) Cognitive impairment risk: White matter hyperintensity progression matters. Neurology 73, 120-125.
43. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, Tanzi RE, Albert MS, Greenberg SM, Guttmann CRG (2008) Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 65, 94-100.
44. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F (2003) Progression of cerebral whi te matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 361, 2046-2048.
45. Longstreth WT, Jr., Arnold AM, Beauchamp NJ, Jr., Manolio TA, Lefkowitz D, Jungreis C, Hirsch CH, O'Leary DH, Furberg CD (2005) Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: The Cardiovascular Health Study. Stroke 36, 56-61.
46. Schmidt R, Berghold A, Jokinen H, Gouw AA, van der Flier WM, Barkhof F, Scheltens P, Petrovic K, Madureir a S, Verdelho A, Ferro JM, Waldemar G, Wallin A, Wahlund LO, Poggesi A, Pantoni L, Inzitari D, Fazekas F, Erkinjuntti T (2012) White matter lesion progression in LADIS: Frequency, clinical effects, and sample s ize calculations. Stroke 43, 2643-2647.
47. Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, Matthews PM, Fazekas F (2005) White matter lesion progression, brain a trophy, and cognitive decline: The Austrian stroke prevention study. Ann Neurol 58, 610-616.
48. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM (2008) Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 39, 2712-2719.
49. Silbert LC, Dodge HH, Perkins LG, Sherbakov L, Lahna D, E rten-Lyons D, Woltjer R, Shinto L, Kaye JA (2012) Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology 79, 741-747.
50. Bombois S, Debette S, Bruandet A, Delbeuck X, Delmaire C, Leys D, Pasquier F (2008) Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients. Stroke 39, 2046-2051.
51. Cl erici F, Caracciolo B, Cova I, Fusari Imperatori S, Maggiore L, Galimberti D, Scarpini E, Mariani C, Fratiglioni L (2012) Does vascular burden contribute to the progression of mild cognitive impairment to dementia? Dem ent Geriatr Cogn Disord 34, 235-243.
52. DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, Jagust W (2004) Memory impairment, but not cerebrovascular disease, predicts progression o f MCI to dementia. Neurology 63, 220-227.
53. Defrancesco M, Marksteiner J, Deisenhammer E, Kemmler G, Djurdjevic T, Schocke M (2013) Impact of white matter lesions and cognitive deficits on conversion from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 34, 665-672.
54. Devine ME, Fonseca JA, Walker Z (2013) Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia? Int Psychogeriatr 25, 120-127.
55. Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, Zanetti O, Frisoni GB (2006) Media l temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry 77, 1219-1222.
56. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, Negash S, Knopman DS, Boeve BF, O'Brien PC, Petersen RC, JackCRJr., (2009) Risk of dementia in MCI: Combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 72, 1519-1525.
57. Korf ES, Wahlund LO, Visser PJ, Scheltens P (2004) Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 63, 94-100.
58. Prins ND, van der Flier WM, Brashear HR, Knol DL, van de Pol LA, Barkhof F, Scheltens P (2013) Predictors of progression from mild cognitive impairment to dementia in the placebo-Arm of a clinical tri al population. J Alzheimers Dis 36, 79-85.
59. Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, Guzman VA, Meier IB, Zimmerman ME, Brickman AM (2013) White matter hyperintensities and cerebral amyloidosis: Necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol 70, 455-461.
60. Staekenborg SS, Koedam EL, Henneman WJ, Stokman P, Barkhof F, Scheltens P, van der Flier WM (2009) Progression of mild cognitive impairment to dementia: Contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 40, 1269-1274.
61. Tapiola T, Pennanen C, Tapiola M, Te rvo S, Kivipelto M, Hanninen T, Pihlajamaki M, Laakso MP, Hallikainen M, Hamalainen A, Vanhanen M, Helkala EL, Vanninen R, Nissinen A, Rossi R, Frisoni GB, Soininen H (2008) MRI of hippocampus a nd entorhinal cortex in mild cognitive impairment: A follow-up study. Neurobiol Aging 29, 31-38.
62. van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR, Jr., DeCarli C (2008) Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol 255, 1302-1308.
63. Haight TJ, Landau SM, Carmichael O, Schwarz C, DeCarli C, Jagust WJ (2013) Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol 70, 1039-1045.
64. Benedictus MR, Goos JD, Binnewijzend MA, Muller M, Barkhof F, Scheltens P, Prins ND, van der Flier WM (2013) Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiol Aging 3 4, 2488-2494.
65. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM (2006) Plasma beta-Amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66, 23-29.
66. Hedden T, Mormino EC, Amariglio RE, Younger AP, Schultz AP, Becker JA, Buckner RL, Johnson KA, Sperling RA, Rentz DM (2012) Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci 32, 16233-16242.
67. Marchant NL, Reed BR, DeCarli CS, Madison CM, We iner MW, Chui HC, Jagust WJ (2012) Cerebrovascular disease, beta-Amyloid, and cognition in aging. Neurobiol Aging 33 1006, e1025-e1036.
68. Marchant NL, Reed BR, Sanossian N, Madison CM , Kriger S, Dhada R, Mack WJ, Decarli C,WeinerMW, Mungas DM, Chui HC, Jagust WJ (2013) The aging brain and cognition: Contribution of vascular injury and abeta to mild cognitive dysfunction. JAMA Neurol 70, 488-495.
69. van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, BretelerMM(2004) Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55, 570-575.
70. Noh Y, Seo SW, Jeon S, Lee JM, Kim JH, Kim GH, Cho H, Yoon CW, Kim HJ, Ye BS, Kim ST, Choe YS, Lee KH, Kim JS, Ewers M, Weiner MW, Lee JH, Werring DJ, Kang DR, Kim CS, Na DL (2014) White matter hyperintensities are associated with amyloid burden in APOE4 non-carriers. J Alzheimers Dis 40, 877-886.
71. Stenset V, Hofoss D, J ohnsen L, Berstad AE, Negaard A, Skinningsrud A, Gjerstad L, Fladby T (2011) White matter lesion load increases the risk of low CSF Abeta42 in apolipoprotein E-varepsilon4 carriers attending a memory clinic. J Neuroimagi ng 21, e78-82.
72. Grimmer T, Faust M, Auer F, Alexopoulos P, Forstl H, Henriksen G, Perneczky R, Sorg C, Yousefi BH, Drzezga A, Kurz A (2012) White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol Aging 33, 2766-2773.
73. Lo RY, Jagust WJ (2012) Vascular burden and Alzheimer disease pathologic progression. Neurology 79, 1349-1355.
74. Mortamais M, Reynes C, Brickman AM, Provenzano FA, Muraskin J, Portet F, Berr C, Touchon J, Bonafe A, le Bars E, Maller JJ, Meslin C, Sabatier R, Ritchie K, Artero S (2013) S patial distribution of cerebral white matter lesions predicts progression to mild cognitive impairment and dementia. PLoS One 8, e56972.
75. Brickman AM, Zimmerman ME, Paul RH, Grieve SM, Tate DF, Cohen RA, Williams LM, Clark CR, Gordon E (2006) Regional white matter and neuropsychological functioning across the adult lifespan. Biol Psychiatry 60, 444-453.
76. Tullberg M, Fletcher E, DeCarli C, Mungas D, Reed BR, Harvey DJ, Weiner MW, Chui HC, Jagust WJ (2004) White matter lesions impair frontal lobe function regardless of their location. Neurolo gy 63, 246-253.
77. Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne JO (2009) In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 72, 1504-1511.
78. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ (2009) Episodic memory loss is related to hippocampalmediated beta-Amyloid deposition in eld erly subjects. Brain 132, 1310-1323.
79. Knopman DS, Jack CR, Jr.,Wiste HJ,Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC (2013) Brain injury biomarkers are not dependent on beta-Amyloid in normal elderly. Ann Neurol 73, 472-480.
80. Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ ( 2013) Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-Amyloid in cognitively normal older individuals. J Neurosci 33, 5553-5563.
81. den Heijer T, van der Lijn F, Ikram A, Koudstaal PJ, van der Lugt A, Krestin GP, Vrooman HA, Hofman A, Niessen WJ, Breteler MM (2012) Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-up. Alzheimers Dement 8, 417-425.
82. Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, Rabinovici GD, Jagust WJ (2013) Associations between Alzheim er disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70, 1512-1519.
83. Barnes J, Carmichael OT, Leung KK, Schwarz C, Ridgway GR, Bartlett JW, Malone IB, Schott JM, Rossor MN, Biessels GJ, DeCarli C, Fox NC (2013) Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiol Aging 3 4, 1996-2002.
84. Guzman VA,Carmichael OT,Schwarz C,Tosto G,Zimmerman ME,Brickman AM(2013 White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume am ong individuals with mild cognitive impairment Alzheimers Dement 9, S124-131
85. Alonso A, Mosley TH, Jr., GottesmanRF, Catellier D, Sharrett AR, Coresh J (2009) Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: The Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry 80, 1194-1201.
86. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
87. Leys D, Pruvo JP, Parent M, Vermersch P, Soetaert G, Steinling M, Delacourte A, Defossez A, Rapoport A, Clarisse J et al. (1991) CouldWallerian degeneration contribute to "leukoaraiosis " in subjects free of any vascular disorder? J Neurol Neurosurg Psychiatry 54, 46-50.
88. Costanza A, Xekardaki A, Kovari E, Gold G, Bouras C, Giannakopoulos P (2012) Microvascular burden and Alzheimer-type lesions across the age spectrum. J Alzheimers Dis 32, 643-652.